Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir
Nature Medicine · 2025
DOI: 10.1038/s41591-024-03357-0 ↗Kurz gefasst
Fallbericht in der Zeitschrift Nature Medicine, 2025. Verfasst von M Ali Rai und 23 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Multiple, Viral, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4+ T cell count. A longitudinal examination of plasma HIV and infectious isolates showed no evidence of viral evolution or the emergence of UB-421- or lenacapavir-resistant viruses. The individual received three cycles of liposomal doxorubicin and five doses of anti-programmed cell death protein 1 (PD-1) monoclonal antibody pembrolizumab that resulted in improvement in KS with flattening of lesions. Our data demonstrate that combination therapy with UB-421 could provide sustained virologic suppression in people harboring MDR HIV with limited therapeutic alternatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
- Leidos Biomedical Research, Frederick, MD, USA.
- Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, USA.
- Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Förderung
- NIH HHS
- Intramural NIH HHS
Zitieren
APA
Rai, M. A., Blazkova, J., Kardava, L., Justement, J. S., Shi, V., Manning, M. R., Shahid, A., Dong, W., Kennedy, B. D., Sewack, A. B., Higgins, J., Buckner, C. M., Gittens, K., West, R. E., Devanathan, A. S., Mangusan, R., Lurain, K., Ramaswami, R., Yarchoan, R., …, & Chun, T. W. (2025). Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir. Nature Medicine. https://doi.org/10.1038/s41591-024-03357-0
Vancouver
Rai MA, Blazkova J, Kardava L, Justement JS, Shi V, Manning MR, et al. Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir. Nature Medicine. 2025. doi:10.1038/s41591-024-03357-0
BibTeX
@article{Rai2025,
author = {Rai, M Ali and Blazkova, Jana and Kardava, Lela and Justement, Jesse S and Shi, Victoria and Manning, Maegan R and Shahid, Aniqa and Dong, Winnie and Kennedy, Brooke D and Sewack, Adeline B and Higgins, Jeanette and Buckner, Clarisa M and Gittens, Kathleen and West, Raymond E and Devanathan, Aaron S and Mangusan, Ralph and Lurain, Kathryn and Ramaswami, Ramya and Yarchoan, Robert and Sneller, Michael C and Pau, Alice K and Brumme, Zabrina L and Moir, Susan and Chun, Tae-Wook},
title = {Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-024-03357-0}
}
EUVIMED